Willenburg says it’s unfair to compare J&J to the Pfizer and Moderna vaccines, which were developed and tested at different phases of the pandemic.
“The Johnson and Johnson vaccine was tested at a different time. So it s tested on a different population with different variants circulating. So you can t directly compare the numbers,” she said.
Will the vaccines protect against variant viruses?
New strains come as the virus mutates and spreads throughout the globe.
The
UK variant is now the most common strain in the U.S. Ones from Brazil and South Africa are present in the states, too. All are either
Dr. Fauci, former Secretary Condoleeza Rice to play part in local college graduations | The Daily Gazette
SECTIONS
April 20, 2021
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks during a House Select Subcommittee hearing on Capitol Hill in Washington April 15, 2021. (Amr Alfiky/The New York Times via AP, Pool)
Shares0
Some big names in national politics will be playing a role in the graduation ceremonies of Capital Region colleges this spring.
Anthony Fauci, director of the U.S. National Institute of Allergy and Infections Diseases and the central federal official in the nation’s response to the COVID-19 pandemic, will be honored as part of Rensselaer Polytechnic Institute’s commencement ceremony on May 22. And former Secretary of State Condoleeza Rice is slated to serve as a virtual commencement speaker for the May 30 Siena College graduation ceremony.
All Adults Now Eligible for COVID-19 Vaccine in US - MedicineNet Health News medicinenet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicinenet.com Daily Mail and Mail on Sunday newspapers.
ResearchAndMarkets.com s offering.
The dengue vaccines market is expected to expand rapidly following the anticipated launch of TAK-003 in 2021/22.
The pipeline remains active with two late-phase live-attenuated vaccines (LAVs), Takeda s TAK-003 and Merck & Co s TV003/TV005, in development in dengue-endemic regions.
TV003/TV005 was initially developed by the US National Institute of Allergy and Infectious Diseases (NIAID) and has been licensed to the Butantan Institute in Brazil, where it is in Phase III trials; Merck & Co in the US, Canada, China, Europe, and Japan; and various other developers in India, the Middle East, and Asia-Pacific markets, with the goal of ensuring market access by facilitating cheaper domestic production in key dengue-endemic regions.